Restoration of Cognitive Function With TDCS and Training in Schizophrenia



Status:Recruiting
Conditions:Schizophrenia
Therapuetic Areas:Psychiatry / Psychology
Healthy:No
Age Range:18 - 60
Updated:1/31/2019
Start Date:July 15, 2018
End Date:September 30, 2021
Contact:Tasha M Nienow, PhD
Email:Tasha.Nienow@va.gov
Phone:(612) 467-1004

Use our guide to learn which trials are right for you!

Development of interventions that can effectively target and remediate the cognitive and
functional impairment associated with schizophrenia is a treatment priority. Transcranial
direct current stimulation (tDCS) is a safe, non-invasive neuromodulation technique that is
capable of stimulating brain activity to facilitate learning. The primary objective of this
study is to evaluate the pairing of two therapeutic techniques, cognitive remediation and
tDCS, as a cognitively enhancing intervention. This study is designed to address four
questions. Is cognitive remediation paired with tDCS more efficacious than cognitive
remediation delivered with sham stimulation? Is it possible to predict responsiveness to the
intervention? Is intervention-induced cognitive change sustainable? Are there barriers to
implementing this intervention in clinical practice?

To examine the incremental benefit of pairing tDCS with cognitive remediation, a 110
clinically stable outpatients between the ages of 18-60 who have a diagnosis of schizophrenia
or schizoaffective disorder will be enrolled in a double-blind, double-baseline,
sham-controlled clinical trial. Participants will be randomized in a 1:1 ratio to receive
either tDCS or sham stimulation concurrent with working memory focused cognitive remediation.
Training will be offered to participants in a small group format. Training will consist of 48
sessions, with 2-3 sessions scheduled in a week. Each training session will last 2 hours. One
hour will be spent completing cognitive exercises that require working memory skills on a
computer. TDCS or sham stimulation will be offered concurrent with the first 20 minutes of
training with a StarStim neuromodulator. One mA of anodal stimulation will be applied to the
left dorsal lateral prefrontal cortex and the cathodal electrode will be placed in the
contralateral supraorbital position. Upon completion of working memory training, participants
will transition to a 30-minute discussion group. The discussion will focus on application of
cognitive skills in everyday life. Effective strategies for approaching cognitive tasks will
be described and practiced. Participant experience with aspects of the training will be
monitored with self-report measures of motivation, mood, and physical reactions. To assess
intervention-induced change, working memory, other aspects of cognition, functional capacity,
and community functioning will be assessed pre- and post-intervention. Cognitive outcomes
will be assessed with training tasks as well as tasks that are unfamiliar to participants. A
performance-based measure will be used to assess functional capacity for everyday living
skills and a self-report instrument will be used to assess community functioning. Potential
confounds such as symptom severity, medication changes, outside treatment hours, and
significant life stressors will be assessed individually every 2 weeks during the
intervention phase of the study. Sustainability of intervention-induced change will be
assessed with assessment sessions 6 weeks and 6 months post-intervention. Change in
performance during the first 12 training sessions on two working memory training tasks, a
n-back task and a complex span task, will be used to determine if early response to treatment
is predictive of post-intervention outcomes. An intent-to-treat analysis will be used to
analyze intervention-induced change. Regression analyses will be conducted to identify
predictors of treatment response.

Achieving the proposed objectives will yield important information about the efficacy,
durability, and efficiency of a novel pairing of cognitively enhancing interventions.
Findings will inform treatment development for patients with schizophrenia as well for
patients with other cognitively compromising illnesses.


Inclusion Criteria:

- Participants are eligible for the study if they have a diagnosis of schizophrenia or
schizoaffective disorder and are clinically stable at the time of enrollment

- defined as not severely depressed or acutely manic and no hospitalizations or
antipsychotic medication changes in the four weeks prior to enrollment

Exclusion Criteria:

- Met criteria for a severe alcohol or substance use disorder in the last 6 months

- Met criteria for a mild alcohol or substance use disorder in the last month

- A history of head injury or neurological disease that has compromised cognitive
functioning

- Ability to speak English is not sufficient to understand study procedures

- Diagnosis of learning disability, mental retardation, or pervasive developmental
disorder

- Diagnosis of a medical condition that is incompatible with tDCS procedures

- Participant does not demonstrate understanding of study procedures during the consent
process

- A documented history of behavioral problems that prevent participation in a group
intervention

- Participated in a study of tDCS or cognitive remediation in the previous 12 months
We found this trial at
1
site
Minneapolis, Minnesota 55417
Principal Investigator: Tasha Marie Nienow, PhD
Phone: (612) 467-1847
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials